ATLANTA, July 06, 2017 (GLOBE NEWSWIRE) -- INCUMAKER, INC. (OTC Pink:QMKR), wished to update its shareholders of the previously announced merger termination of CEN Biotech, Inc. with its subsidiary, Eastern Starr Biotech, Inc.

As a result of the termination, Incumaker will not be issuing 100 million shares of common stock to CEN Biotech, nor will it be assuming any debt or liabilities associated with CEN Biotech. Incumaker has resumed its communications with other potential merger partners with a goal of identifying opportunities that will allow Incumaker to increase shareholder value.

In addition, the Company has retained an auditor to complete its 2 year PCAOB audit and expects the audit to be completed in July 2017. This is a necessary step for Incumaker to uplist to the OTC QB marketplace and to become a SEC compulsory filer.

About Incumaker:

Incumaker, Inc. (OTC Pink:QMKR) is a diversified holding company whose strategic plan is to acquire interests in young businesses, and provide financing, advice and guidance to assist them in realizing their potential. The company’s wholly owned subsidiary, Eastern Starr Biotech, is pursuing strategic acquisitions in the Cannabis industries. We continue to identify and evaluate other potential acquisitions that we believe will create shareholder value and return. For additional information please email Incumaker@gmail.com.